Law, Politics, and Expert Panels at the US Food and Drug Administration | Synapse
February 16, 2026Open Access
Law, Politics, and Expert Panels at the US Food and Drug Administration
Key Points
The central aim is to evaluate the legality and reliability of using expert panels instead of traditional advisory committees at the FDA.
Analytical viewpoint on the FDA's decision-making process.
Discussion of legal frameworks governing the FDA.
Evaluation of credibility concerns related to expert panels.
Highlights concerns about the legitimacy of expert panels.
Suggests that using expert panels may undermine public trust.
Calls for clarity in the FDA's decision-making criteria.
Abstract
This Viewpoint discusses the lawfulness and credibility of the US Food and Drug Administration’s recent move to using expert panels rather than advisory committees for decision-making.